Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 02, 2025, titled "Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA � CD38 � CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma".